









Markets
/
Stocks
/
nasdaq-entx
/

Entera Bio Ltd

ENTX



View Detailed Chart

1.770USD

-0.170-8.76%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

80.83MMarket Cap

LossP/E TTM



Entera Bio Ltd

1.770

-0.170-8.76%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-8.76%

5 Days

-18.06%

1 Month

-30.04%

6 Months

-10.61%

Year to Date

-16.51%

1 Year

-15.71%

View Detailed Chart

TradingKey Stock Score of Entera Bio Ltd

Currency: USD Updated: 2025-12-19

Key Insights

Entera Bio Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 151/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Entera Bio Ltd's Score

Industry at a Glance

Industry Ranking

151 / 404

Overall Ranking

279 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 1 analysts

Buy

Current Rating

10.000

Target Price

+369.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Entera Bio Ltd Highlights

StrengthsRisks

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 35.07% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 181.00K.

Fairly Valued

The company’s latest PE is -7.26, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 88.40K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.48.